Cancer prevention
著者
書誌事項
Cancer prevention
（Recent results in cancer research, v. 174,
Springer Berlin, 2007-
- [I]
- II
大学図書館所蔵 件 / 全11件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Editors of v. II: Hans-Jörg Senn, Ursula Kapp, Florian Otto
Includes bibliographical references
内容説明・目次
- 巻冊次
-
[I] ISBN 9783540376958
内容説明
This volume contains the main proceedings of the fourth international conference on "Cancer Prevention 2006," which was held during February 16-18, 2006, in St. Gallen, Switzerland. Written by international experts in the field, the book comprises a comprehensive update on the most recent developments in the upsurging fields of molecular biology and cancer genetics and their interactions with clinical epidemiology and cancer prevention at various levels.
目次
Genetic risk profiles and biomarkers in cancer prevention: Progress in cancer prevention and screening. Genetic risk profiles for cancer susceptibility and therapy response. Tumor promotion as a target of cancer prevention. Insulin-like growth factor-related signaling and cancer development. Inflammation, infection, and cancer prevention: Cytokines are a therapeutic target for the prevention of inflammation-induced cancers. Prevention of hepatocellular carcinoma in chronic viral hepatitis patients with cirrhosis by carotenoid mixture. Cox-2 and cancer chemoprevention.- Prevention of female and male genital cancers: Human Papillomavirus vaccine: a new chance to prevent cervical cancer. Prevention and early detection of ovarian cancer. Prevention of prostate cancer. Primary prevention of breast cancer by hormone-induced differentiation.- Prevention of breast cancer: The genomic signature of breast cancer prevention. Estrogen deprivation for breast cancer prevention.- Prevention of colorectal and renal cancers: Primary dietary prevention. Prevention and early detection of colorectal cancer.- Prevention of skin, brain, and lung tumors: New perspectives on melanoma pathogenesis and chemoprevention. Vitamin D - an emerging issue in skin cancer control. Implications for public health practice based on the Australian experience. Are gliomas preventable?- The future of cancer (chemo)prevention: Angiogenesis and cancer prevention. An estimate of cancer mortality rate reductions in Europe and the US with 1,000 IU of oral vitamin D per day. Uncovering novel targets for cancer chemoprevention.- Conference summary.
- 巻冊次
-
II ISBN 9783540692966
内容説明
More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK). While SONK has been extremely successful in organizing large international c- gresses on "Primary Therapy of Early Breast Cancer" as well as "Supportive Care in Cancer" for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and w- comed concept in modern oncology. Since today's medical expenses are soaring and me- cal research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts! In Switzerland-and we fear in many other parts of the globe-some 97%-98% or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative m- icine. Since a meager 2%-3% of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for "curing and caring" for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population.
目次
Cancer Prevention and Health Politics. Do we make optimal use of the potential of cancer prevention? Predictors of successful cancer prevention programs. Cancer prevention in the developing world: mission impossible?Is cancer prevention ever going to be profitable?.- Cancer Prevention: The Scientific-Epidemiological Base. Energy metabolism, cancer risk, and cancer prevention. Promises and limitations of biomarkers.- Cancer Prevention, Tobacco and Nutrition. The EPIC study: an update. Anti-angiogenic properties of chemopreventive drugs: Fenretinide as a prototype. Retinoids and breast cancer prevention.- Cancer Prevention, Genetics and Vaccines. Cancer prevention by vaccination against hepatitis B.- Cancer Prevention and Target Organs I: Breast Cancer. Energy restriction for breast cancer prevention. The use of Tamoxifen and Raloxifene for the prevention of breast cancer. Prevention of ER-negative breast cancer. Exogenous and endogenous hormones, mammographic density and breast cancer risk - can mammographic density be considered an intermediate marker of risk?.- Cancer Prevention and Target Organs II: Cancer of the Digestive Tract. Chemoprevention of oesophageal cancer and the AspECT trial.- Cancer Prevention and Target Organs III: Prostate Cancer. Review of diagnostic markers for prostate cancer. Selenium and vitamin E cancer prevention trial (SELECT): a nutrient approach to prostate cancer prevention. Prostate cancer prevention by short-term anti-androgens: the rationale behind design of pilot studies.- Cancer Prevention: Metabolic Aspects. Anti-angiogenic activity of a novel class of chemopreventive compounds: oleanic acid terpenoids.- Aspirin and NSAIDs in Cancer Prevention: Attempts at an International Consensus. Pharmacologic effects of NSAIDs and implications for the risks and benefits of long-term prophylactic use of asprin to prevent cancer. Aspirin and NSAIDs for the prevention of colorectal cancer. Aspirin and cancer risk: a summary review.
「Nielsen BookData」 より
